2023

Seitz, J., Bilsland, A. , Puget, C., Baasner, I., Klopfleisch, R. and Stein, T. (2023) SFRP1 expression is inversely associated with metastasis formation in canine mammary tumours. Journal of Mammary Gland Biology and Neoplasia, 28(1), p. 15. (doi: 10.1007/s10911-023-09543-z) (PMID:37402051)

2021

Ibrahim, A., Bilsland, A. , Rickelt, S., Morris, J. and Stein, T. (2021) A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans. Breast Cancer Research, 23, 90. (doi: 10.1186/s13058-021-01470-3) (PMID:34565423) (PMCID:PMC8474794)

2019

Bilsland, A. E. , Liu, Y., Turnbull, A., Sumpton, D., Stevenson, K., Cairney, C. J., Boyd, S. M., Roffey, J., Jenkinson, D. and Keith, W. N. (2019) A novel pyrazolopyrimidine ligand of human PGK1 and stress sensor DJ1 modulates the shelterin complex and telomere length regulation. Neoplasia, 21(9), pp. 893-907. (doi: 10.1016/j.neo.2019.07.008) (PMID:31401411) (PMCID:PMC6700475)

2018

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)

2017

Cairney, C. J. et al. (2017) A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genetics, 13(8), e1006942. (doi: 10.1371/journal.pgen.1006942) (PMID:28806777) (PMCID:PMC5570495)

2016

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi: 10.1097/PAI.0000000000000357) (PMID:27093449)

2015

Amin, A.R.M. R. et al. (2015) Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology, 35, S55-S77. (doi: 10.1016/j.semcancer.2015.02.005) (PMID:25749195) (PMCID:PMC4561219)

Casey, S. C. et al. (2015) Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology, 35, S199-S223. (doi: 10.1016/j.semcancer.2015.02.007) (PMID:25865775) (PMCID:PMC4930000)

Feitelson, M. A. et al. (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Seminars in Cancer Biology, 35(Suppl), S25-S54. (doi: 10.1016/j.semcancer.2015.02.006) (PMID:25892662) (PMCID:PMC4898971)

Ferguson, L. R. et al. (2015) Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 35(Suppl), S5-S24. (doi: 10.1016/j.semcancer.2015.03.005) (PMID:25869442) (PMCID:PMC4600419)

Mohammad, R. M. et al. (2015) Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 35(Suppl.), S78-S103. (doi: 10.1016/j.semcancer.2015.03.001) (PMID:25936818)

Samadi, A. K. et al. (2015) A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 35(Suppl), S151-S184. (doi: 10.1016/j.semcancer.2015.03.006) (PMID:25951989) (PMCID:PMC4635070)

Vinay, D. S. et al. (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 35(Suppl.), S185-S198. (doi: 10.1016/j.semcancer.2015.03.004) (PMID:25818339)

Wang, Z. et al. (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology, 35(Suppl.), S224-S243. (doi: 10.1016/j.semcancer.2015.01.001) (PMID:25600295) (PMCID:PMC4737670)

Yaswen, P. et al. (2015) Therapeutic targeting of replicative immortality. Seminars in Cancer Biology, 35(Supp.), S104-S128. (doi: 10.1016/j.semcancer.2015.03.007) (PMID:25869441) (PMCID:PMC4600408)

Bilsland, A. E. et al. (2015) Identification of a selective G1-phase benzimidazolone inhibitor by a senescence-targeted virtual screen using artificial neural networks. Neoplasia, 17(9), pp. 704-715. (doi: 10.1016/j.neo.2015.08.009) (PMID:26476078) (PMCID:PMC4611071)

Hartmann, D., von Figura, G., Song, Z., Harden, S., Scott, L. C., Evans, T. J. , Rudolph, K. L., Bilsland, A. E. and Keith, W. N. (2015) PlasmaN-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome. Future Oncology, 11(2), pp. 193-203. (doi: 10.2217/fon.14.166)

2014

Bilsland, A. E. , Stevenson, K., Liu, Y., Hoare, S., Cairney, C. J., Roffey, J. and Keith, W. N. (2014) Mathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanisms. PLoS Computational Biology, 10(2), e1003448. (doi: 10.1371/journal.pcbi.1003448) (PMID:24550717) (PMCID:PMC3923661)

2013

Bilsland, A. E. , Revie, J. and Keith, W.N. (2013) MicroRNA and senescence: the senectome, integration and distributed control. Critical Reviews in Oncogenesis, 18(4), pp. 373-390. (doi: 10.1615/CritRevOncog.2013007197)

2012

Cairney, C.J., Bilsland, A.E. , Evans, T.R.J. , Roffey, J., Bennett, D.C., Narita, M., Torrance, C. and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17(5-6), pp. 269-276. (doi: 10.1016/j.drudis.2012.01.019)

Keith, W.N. , Lafferty-Whyte, K., Cairney, C.J., Zaffaroni, N. and Bilsland, A. (2012) Response to ‘Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanism. Oncogene, 31(2), pp. 267-268. (doi: 10.1038/onc.2011.374)

2011

Bilsland, A.E. , Cairney, C.J. and Keith, W.N. (2011) Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. Journal of Cellular and Molecular Medicine, 15(2), pp. 179-186. (doi: 10.1111/j.1582-4934.2010.01253.x)

2010

Lafferty-Whyte, K., Bilsland, A. , Hoare, S.F., Burns, S., Zaffaroni, N., Cairney, C.J. and Keith, W.N. (2010) TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia, 12(5), pp. 405-414.

Bilsland, A. E. and Keith, W. N. (2010) Mining cellular senescence for drug targets. In: Adams, Peter. D. and Sedivy, John M. (eds.) Cellular Senescence and Tumor Suppression. Springer: New York, pp. 235-266. ISBN 9781441910745 (doi: 10.1007/978-1-4419-1075-2_10)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi: 10.1186/1471-2164-11-532)

Stolzenburg, S., Bilsland, A. , Keith, W.N. and Rots, M.G. (2010) Modulation of gene expression using zinc finger-based artificial transcription factors. Methods in Molecular Biology, 649(2), pp. 117-132. (doi: 10.1007/978-1-60761-753-2_7)

2009

Lafferty-Whyte, K., Cairney, C.J., Will, M.B., Serakinci, N., Daidone, M.G., Zaffaroni, N., Bilsland, A.E. and Keith, W.N. (2009) A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 28(43), pp. 3765-3774. (doi: 10.1038/onc.2009.238)

Bilsland, A.E., Hoare, S.F., Stevenson, K.H., Plumb, J.A., Gomez-Roman, N. , Cairney, C.J., Burns, S., Lafferty-Whyte, K., Hammonds, T. and Keith, W.N. (2009) Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE, 4(7), e6459. (doi: 10.1371/journal.pone.0006459) (PMID:19649288) (PMCID:PMC2714081)

2008

Keith, W.N. and Bilsland, A.E. (2008) Targeting telomerase: therapeutic options for cancer treatment. In: Rudolph, K.L. (ed.) Telomeres and Telomerase in Aging, Disease, and Cancer: Molecular Mechanisms of Adult Stem Cell Ageing. Springer: Berlin, Germany, pp. 247-283. ISBN 9783540737087 (doi: 10.1007/978-3-540-73709-4_13)

2007

Bilsland, A.E. , Merron, A., Vassaux, G. and Keith, W.N. (2007) Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Research, 67(3), pp. 1299-1307. (doi: 10.1158/0008-5472.CAN-06-3000)

2006

Anderson, C.J., Hoare, S.F., Ashcroft, M., Bilsland, A.E. and Keith, W.N. (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene, 25(1), pp. 61-69. (doi: 10.1038/sj.onc.1209011)

2005

Zhao, J., Bilsland, A. , Jackson, K. and Keith, W.N. (2005) MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer, 5, 6. (doi: 10.1186/1471-2407-5-6) (PMID:15656906) (PMCID:PMC546012)

Bilsland, A.E. , Fletcher-Monaghan, A. and Keith, W.N. (2005) Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia, 7(11), pp. 1020-1029. (doi: 10.1593/neo.05385)

Dufes, C., Keith, W.N. , Proutski, I., Bilsland, A. , Uchegbu, I.F. and Schõtzlein, A.G. (2005) Synthetic anti-cancer gene medicine exploits intrinsic anti-tumour activity of cationic vector to cure established tumours. Cancer Research, 65(18), pp. 8079-8084. (doi: 10.1158/0008-5472.CAN-04-4402)

2004

Keith, W.N. et al. (2004) A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. BMC Blood Disorders, 4(3), (doi: 10.1186/1471-2326-4-3)

Keith, W. , Bilsland, A. , Hardie, M. and Evans, T. (2004) Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, 1(2), pp. 88-96. (doi: 10.1038/ncponc0044)

2003

Bilsland, A.E. , Anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R.J. , Ganly, I., Knox, R.J., Plumb, J.A. and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22(3), pp. 370-380. (doi: 10.1038/sj.onc.1206168)

Zhao, J.Q., Bilsland, A. , Hoare, S.F. and Keith, W.N. (2003) Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Letters, 536(1-3), pp. 111-119. (doi: 10.1016/S0014-5793(03)00038-3)

2002

Keith, W.N. , Bilsland, A. , Evans, T.R.J. and Glasspool, R.M. (2002) Telomerase-Directed Molecular Therapeutics. Expert Reviews in Molecular Medicine(4), pp. 1-25. (doi: 10.1017/S1462399402004507)

2001

Plumb, J.A., Bilsland, A. , Kakani, R., Zhao, J.Q., Glasspool, R.M., Knox, R.J., Evans, T.R.J. and Keith, W.N. (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20(53), pp. 7797-7803.

2000

Zhao, J.Q., Glasspool, R.M., Hoare, S.F., Bilsland, A. , Szatmari, I. and Keith, W.N. (2000) Activation of telomerase RNA gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia, 2(6), pp. 531-539.

Articles

Seitz, J., Bilsland, A. , Puget, C., Baasner, I., Klopfleisch, R. and Stein, T. (2023) SFRP1 expression is inversely associated with metastasis formation in canine mammary tumours. Journal of Mammary Gland Biology and Neoplasia, 28(1), p. 15. (doi: 10.1007/s10911-023-09543-z) (PMID:37402051)

Ibrahim, A., Bilsland, A. , Rickelt, S., Morris, J. and Stein, T. (2021) A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans. Breast Cancer Research, 23, 90. (doi: 10.1186/s13058-021-01470-3) (PMID:34565423) (PMCID:PMC8474794)

Bilsland, A. E. , Liu, Y., Turnbull, A., Sumpton, D., Stevenson, K., Cairney, C. J., Boyd, S. M., Roffey, J., Jenkinson, D. and Keith, W. N. (2019) A novel pyrazolopyrimidine ligand of human PGK1 and stress sensor DJ1 modulates the shelterin complex and telomere length regulation. Neoplasia, 21(9), pp. 893-907. (doi: 10.1016/j.neo.2019.07.008) (PMID:31401411) (PMCID:PMC6700475)

Cairney, C. J. et al. (2017) A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genetics, 13(8), e1006942. (doi: 10.1371/journal.pgen.1006942) (PMID:28806777) (PMCID:PMC5570495)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi: 10.1097/PAI.0000000000000357) (PMID:27093449)

Amin, A.R.M. R. et al. (2015) Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology, 35, S55-S77. (doi: 10.1016/j.semcancer.2015.02.005) (PMID:25749195) (PMCID:PMC4561219)

Casey, S. C. et al. (2015) Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology, 35, S199-S223. (doi: 10.1016/j.semcancer.2015.02.007) (PMID:25865775) (PMCID:PMC4930000)

Feitelson, M. A. et al. (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Seminars in Cancer Biology, 35(Suppl), S25-S54. (doi: 10.1016/j.semcancer.2015.02.006) (PMID:25892662) (PMCID:PMC4898971)

Ferguson, L. R. et al. (2015) Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 35(Suppl), S5-S24. (doi: 10.1016/j.semcancer.2015.03.005) (PMID:25869442) (PMCID:PMC4600419)

Mohammad, R. M. et al. (2015) Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 35(Suppl.), S78-S103. (doi: 10.1016/j.semcancer.2015.03.001) (PMID:25936818)

Samadi, A. K. et al. (2015) A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 35(Suppl), S151-S184. (doi: 10.1016/j.semcancer.2015.03.006) (PMID:25951989) (PMCID:PMC4635070)

Vinay, D. S. et al. (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Seminars in Cancer Biology, 35(Suppl.), S185-S198. (doi: 10.1016/j.semcancer.2015.03.004) (PMID:25818339)

Wang, Z. et al. (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology, 35(Suppl.), S224-S243. (doi: 10.1016/j.semcancer.2015.01.001) (PMID:25600295) (PMCID:PMC4737670)

Yaswen, P. et al. (2015) Therapeutic targeting of replicative immortality. Seminars in Cancer Biology, 35(Supp.), S104-S128. (doi: 10.1016/j.semcancer.2015.03.007) (PMID:25869441) (PMCID:PMC4600408)

Bilsland, A. E. et al. (2015) Identification of a selective G1-phase benzimidazolone inhibitor by a senescence-targeted virtual screen using artificial neural networks. Neoplasia, 17(9), pp. 704-715. (doi: 10.1016/j.neo.2015.08.009) (PMID:26476078) (PMCID:PMC4611071)

Hartmann, D., von Figura, G., Song, Z., Harden, S., Scott, L. C., Evans, T. J. , Rudolph, K. L., Bilsland, A. E. and Keith, W. N. (2015) PlasmaN-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome. Future Oncology, 11(2), pp. 193-203. (doi: 10.2217/fon.14.166)

Bilsland, A. E. , Stevenson, K., Liu, Y., Hoare, S., Cairney, C. J., Roffey, J. and Keith, W. N. (2014) Mathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanisms. PLoS Computational Biology, 10(2), e1003448. (doi: 10.1371/journal.pcbi.1003448) (PMID:24550717) (PMCID:PMC3923661)

Bilsland, A. E. , Revie, J. and Keith, W.N. (2013) MicroRNA and senescence: the senectome, integration and distributed control. Critical Reviews in Oncogenesis, 18(4), pp. 373-390. (doi: 10.1615/CritRevOncog.2013007197)

Cairney, C.J., Bilsland, A.E. , Evans, T.R.J. , Roffey, J., Bennett, D.C., Narita, M., Torrance, C. and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17(5-6), pp. 269-276. (doi: 10.1016/j.drudis.2012.01.019)

Keith, W.N. , Lafferty-Whyte, K., Cairney, C.J., Zaffaroni, N. and Bilsland, A. (2012) Response to ‘Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanism. Oncogene, 31(2), pp. 267-268. (doi: 10.1038/onc.2011.374)

Bilsland, A.E. , Cairney, C.J. and Keith, W.N. (2011) Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. Journal of Cellular and Molecular Medicine, 15(2), pp. 179-186. (doi: 10.1111/j.1582-4934.2010.01253.x)

Lafferty-Whyte, K., Bilsland, A. , Hoare, S.F., Burns, S., Zaffaroni, N., Cairney, C.J. and Keith, W.N. (2010) TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia, 12(5), pp. 405-414.

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi: 10.1186/1471-2164-11-532)

Stolzenburg, S., Bilsland, A. , Keith, W.N. and Rots, M.G. (2010) Modulation of gene expression using zinc finger-based artificial transcription factors. Methods in Molecular Biology, 649(2), pp. 117-132. (doi: 10.1007/978-1-60761-753-2_7)

Lafferty-Whyte, K., Cairney, C.J., Will, M.B., Serakinci, N., Daidone, M.G., Zaffaroni, N., Bilsland, A.E. and Keith, W.N. (2009) A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 28(43), pp. 3765-3774. (doi: 10.1038/onc.2009.238)

Bilsland, A.E., Hoare, S.F., Stevenson, K.H., Plumb, J.A., Gomez-Roman, N. , Cairney, C.J., Burns, S., Lafferty-Whyte, K., Hammonds, T. and Keith, W.N. (2009) Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE, 4(7), e6459. (doi: 10.1371/journal.pone.0006459) (PMID:19649288) (PMCID:PMC2714081)

Bilsland, A.E. , Merron, A., Vassaux, G. and Keith, W.N. (2007) Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Research, 67(3), pp. 1299-1307. (doi: 10.1158/0008-5472.CAN-06-3000)

Anderson, C.J., Hoare, S.F., Ashcroft, M., Bilsland, A.E. and Keith, W.N. (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene, 25(1), pp. 61-69. (doi: 10.1038/sj.onc.1209011)

Zhao, J., Bilsland, A. , Jackson, K. and Keith, W.N. (2005) MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer, 5, 6. (doi: 10.1186/1471-2407-5-6) (PMID:15656906) (PMCID:PMC546012)

Bilsland, A.E. , Fletcher-Monaghan, A. and Keith, W.N. (2005) Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy. Neoplasia, 7(11), pp. 1020-1029. (doi: 10.1593/neo.05385)

Dufes, C., Keith, W.N. , Proutski, I., Bilsland, A. , Uchegbu, I.F. and Schõtzlein, A.G. (2005) Synthetic anti-cancer gene medicine exploits intrinsic anti-tumour activity of cationic vector to cure established tumours. Cancer Research, 65(18), pp. 8079-8084. (doi: 10.1158/0008-5472.CAN-04-4402)

Keith, W.N. et al. (2004) A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. BMC Blood Disorders, 4(3), (doi: 10.1186/1471-2326-4-3)

Keith, W. , Bilsland, A. , Hardie, M. and Evans, T. (2004) Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, 1(2), pp. 88-96. (doi: 10.1038/ncponc0044)

Bilsland, A.E. , Anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R.J. , Ganly, I., Knox, R.J., Plumb, J.A. and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22(3), pp. 370-380. (doi: 10.1038/sj.onc.1206168)

Zhao, J.Q., Bilsland, A. , Hoare, S.F. and Keith, W.N. (2003) Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene. FEBS Letters, 536(1-3), pp. 111-119. (doi: 10.1016/S0014-5793(03)00038-3)

Keith, W.N. , Bilsland, A. , Evans, T.R.J. and Glasspool, R.M. (2002) Telomerase-Directed Molecular Therapeutics. Expert Reviews in Molecular Medicine(4), pp. 1-25. (doi: 10.1017/S1462399402004507)

Plumb, J.A., Bilsland, A. , Kakani, R., Zhao, J.Q., Glasspool, R.M., Knox, R.J., Evans, T.R.J. and Keith, W.N. (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20(53), pp. 7797-7803.

Zhao, J.Q., Glasspool, R.M., Hoare, S.F., Bilsland, A. , Szatmari, I. and Keith, W.N. (2000) Activation of telomerase RNA gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia, 2(6), pp. 531-539.

Book Sections

Bilsland, A. E. and Keith, W. N. (2010) Mining cellular senescence for drug targets. In: Adams, Peter. D. and Sedivy, John M. (eds.) Cellular Senescence and Tumor Suppression. Springer: New York, pp. 235-266. ISBN 9781441910745 (doi: 10.1007/978-1-4419-1075-2_10)

Keith, W.N. and Bilsland, A.E. (2008) Targeting telomerase: therapeutic options for cancer treatment. In: Rudolph, K.L. (ed.) Telomeres and Telomerase in Aging, Disease, and Cancer: Molecular Mechanisms of Adult Stem Cell Ageing. Springer: Berlin, Germany, pp. 247-283. ISBN 9783540737087 (doi: 10.1007/978-3-540-73709-4_13)

Conference or Workshop Item

Bilsland, A. , Kelly, C. , Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi: 10.1038/s41416-018-0299-z)